Surgical resection of malignant gliomas-role in optimizing patient outcome

Nature Reviews Neurology

Volumn 9, Issue 3, 2013, Pages 141-151

  Eyüpoglu, Ilker Y ^a   Buchfelder, Michael ^a   Savaskan, Nic E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; ISOCITRATE DEHYDROGENASE 1; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMUSTINE; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; TENIPOSIDE; VINCRISTINE;

AGE; BRAIN MAPPING; BRAIN SURGERY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DRUG TOLERABILITY; EPIGENETICS; GENETIC MARKER; GLIOBLASTOMA; HUMAN; INTRAOPERATIVE PERIOD; KARNOFSKY PERFORMANCE STATUS; LIFE EXPECTANCY; MICROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROMOTER REGION; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPIN LABELING; SURGICAL TECHNIQUE; SURVIVAL TIME; TREATMENT OUTCOME;

BRAIN NEOPLASMS; GLIOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; NEUROSURGICAL PROCEDURES; TREATMENT OUTCOME;

EID: 84874946059     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.279     Document Type: Review

References (124)

1. Ohgaki, H. & Kleihues, P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 64, 479-489 (2005).
2. Kohler, B. A. et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J. Natl Cancer Inst. 103, 714-736 (2011).
3. Cancer Genome Atlas Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
4. Central Brain Tumor Registry of the United States [online], http://www.cbtrus.org/ (2012).
5. Wen, P. Y. & Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 359, 492-507 (2008).
6. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009).
7. Mirimanoff, R. O. et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J. Clin. Oncol. 24, 2563-2569 (2006).
8. van den Bent, M. J., Hegi, M. E. & Stupp, R. Recent developments in the use of chemotherapy in brain tumours. Eur. J. Cancer 42, 582-588 (2006).
9. Keles, G. E., Lamborn, K. R. & Berger, M. S. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J. Neurosurg. 95, 735-745 (2001).
10. Johannesen, T. B., Langmark, F. & Lote, K. Progress in long-term survival in adult patients with supratentorial low-grade gliomas: a population-based study of 993 patients in whom tumors were diagnosed between 1970 and 1993. J. Neurosurg. 99, 854-862 (2003).
11. Bussiere, M. et al. Indicators of functional status for primary malignant brain tumour patients. Can. J. Neurol. Sci. 32, 50-56 (2005).
12. Gerstner, E. R. & Batchelor, T. T. Imaging and response criteria in gliomas. Curr. Opin. Oncol. 22, 598-603 (2010).
13. Gore, J. C., Manning, H. C., Quarles, C. C., Waddell, K. W. & Yankeelov, T. E. Magnetic resonance in the era of molecular imaging of cancer. Magn. Reson. Imaging 29, 587-600 (2011).
14. Kondziolka, D., Lunsford, L. D. & Martinez, A. J. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J. Neurosurg. 79, 533-536 (1993).
15. Alesch, F., Pappaterra, J., Trattnig, S. & Koos, W. T. The role of stereotactic biopsy in radiosurgery. Acta Neurochir. Suppl. 63, 20-24 (1995).
16. Cohen, M. H., Johnson, J. R. & Pazdur, R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin. Cancer Res. 11, 6767-6771 (2005).
17. Lai, A. et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29, 142-148 (2011).
18. Stummer, W. et al. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J. Neurooncol. 108, 89-97 (2012).
19. Perry, J. R. et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J. Clin. Oncol. 28, 2051-2057 (2010).
20. Brada, M. et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J. Clin. Oncol. 28, 4601-4608 (2010).
21. Kong, D. S. et al. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol. 12, 289-296 (2010).
22. Clarke, J. L. et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J. Clin. Oncol. 27, 3861-3867 (2009).
23. Desjardins, A. et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118, 1302-1312 (2012).
24. Xu, J. F. et al. Should we reoperate for recurrent high-grade astrocytoma? J. Neurooncol. 105, 291-299 (2011).
25. Wick, A. et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J. Clin. Oncol. 25, 3357-3361 (2007).
26. van den Bent, M. J. et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 27, 1268-1274 (2009).
27. Kubben, P. L. et al. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol. 12, 1062-1070 (2011).
28. Van Meir, E. G. et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J. Clin. 60, 166-193 (2010).
29. Pace, A. et al. Epilepsy in the end-of-life phase in patients with high-grade gliomas. J. Neurooncol. http://dx.doi.org/10.1007/s11060-012-0993-2.
30. Liu, C. Q., Zhou, J., Qi, X. & Luan, G. M. Refractory temporal lobe epilepsy caused by angiocentric glioma complicated with focal cortical dysplasia: a surgical case series. J. Neurooncol. 110, 375-380 (2012).
31. Kubben, P. L., Postma, A. A., Kessels, A. G., van Overbeeke, J. J. & van Santbrink, H. Intraobserver and interobserver agreement in volumetric assessment of glioblastoma multiforme resection. Neurosurgery 67, 1329-1334 (2010).
32. Macdonald, D. R., Cascino, T. L., Schold, S. C. Jr & Cairncross, J. G. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280 (1990).
33. Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963-1972 (2010).
34. Vogelbaum, M. A. et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 70, 234-243 (2012).
35. Sutherland, G. R. et al. A mobile high-field magnetic resonance system for neurosurgery. J. Neurosurg. 91, 804-813 (1999).
36. Nimsky, C., Ganslandt, O., Buchfelder, M. & Fahlbusch, R. Intraoperative visualization for resection of gliomas: the role of functional neuronavigation and intraoperative 1.5 T MRI. Neurol. Res. 28, 482-487 (2006).
37. Nimsky, C., Ganslandt, O., Merhof, D., Sorensen, A. G. & Fahlbusch, R. Intraoperative visualization of the pyramidal tract by diffusion tensor imaging-based fiber tracking. Neuroimage 30, 1219-1229 (2006).
38. Stummer, W. et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 7, 392-401 (2006).
39. Diez Valle, R. et al. Surgery guided by 5 aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J. Neurooncol. 102, 105-113 (2011).
40. Eyüpoglu, I. Y. et al. Improving the extent of malignant glioma resection by dual intraoperative visualization approach. PLoS ONE 7, e44885 (2012).
41. Senft, C. et al. Optimizing the extent of resection in eloquently located gliomas by combining intraoperative MRI guidance with intraoperative neurophysiological monitoring. J. Neurooncol. 109, 81-90 (2012).
42. Pia, H. W. Microsurgery of gliomas. Acta Neurochir. (Wien) 80, 1-11 (1986).
43. Smith, A. & Burklund, C. W. Dominant hemispherectomy: preliminary report on neuropsychological sequelae. Science 153, 1280-1282 (1966).
44. Wilson, C. B. & Barker, M. Intrathecal transplantation of human neural tumors to the guinea pig. J. Natl Cancer Inst. 41, 1229-1240 (1968).
45. McIntosh, D. A. et al. Homotransplantation of a cadaver neoplasm and a renal homograft. JAMA 192, 1171-1173 (1965).
46. Buell, J. F. et al. Donors with central nervous system malignancies: are they truly safe? Transplantation 76, 340-343 (2003).
47. Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828 (2003).
48. Sanai, N., Alvarez-Buylla, A. & Berger, M. S. Neural stem cells and the origin of gliomas. N. Engl. J. Med. 353, 811-822 (2005).
49. Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173 (2006).
50. Galli, R. et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 7011-7021 (2004).
51. Ricci-Vitiani, L. et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468, 824-828 (2010).
52. Wang, R. et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468, 829-833 (2010).
53. Parson, A. B. Stem cell biotech: seeking a piece of the action. Cell 132, 511-513 (2008).
54. Torkamani, A. & Schork, N. J. Identification of rare cancer driver mutations by network reconstruction. Genome Res. 19, 1570-1578 (2009).
55. Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226-231 (2012).
56. Felsberg, J. et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int. J. Cancer 129, 659-670 (2011).
57. Laws, E. R. et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J. Neurosurg. 99, 467-473 (2003).
58. Showalter, T. N. et al. Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int. J. Radiat. Oncol. Biol. Phys. 69, 820-824 (2007).
59. Giles, G. G. & Gonzales, M. F. in Brain Tumors (eds Kaye, A. H. & Laws, E. R.) 51-70 (Churchill Livingstone, New York, 2001).
60. Vecht, C. J., Avezaat, C. J., van Putten, W. L., Eijkenboom, W. M. & Stefanko, S. Z. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J. Neurol. Neurosurg. Psychiatry 53, 466-471 (1990).
61. Burger, P. C. & Green, S. B. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59, 1617-1625 (1987).
62. Davis, F. G., Freels, S., Grutsch, J., Barlas, S. & Brem, S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J. Neurosurg. 88, 1-10 (1998).
63. Ewelt, C. et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. J. Neurooncol. 103, 611-618 (2011).
64. Scott, J. G. et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro Oncol. 13, 428-436 (2011).
65. Stark, A. M., Stepper, W. & Mehdorn, H. M. Outcome evaluation in glioblastoma patients using different ranking scores: KPS, GOS, mRS and MRC. Eur. J. Cancer Care (Engl.) 19, 39-44 (2010).
66. Hassaneen, W. et al. Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. J. Neurosurg. 114, 576-584 (2011).
67. Barker, F. G. 2nd & Chang, S. M. Improving resection of malignant glioma. Lancet Oncol. 7, 359-360 (2006).
68. Louis, D. N. Molecular pathology of malignant gliomas. Annu. Rev. Pathol. 1, 97-117 (2006).
69. Lacroix, M. et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 95, 190-198 (2001).
70. Miller, C. R., Dunham, C. P., Scheithauer, B. W. & Perry, A. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J. Clin. Oncol. 24, 5419-5426 (2006).
71. Homma, T. et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J. Neuropathol. Exp. Neurol. 65, 846-854 (2006).
72. Noch, E. & Khalili, K. Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol. Ther. 8, 1791-1797 (2009).
73. Nelson, J. S. et al. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 52, 550-554 (1983).
74. Muragaki, Y. et al. Usefulness of intraoperative magnetic resonance imaging for glioma surgery. Acta Neurochir. Suppl. 98, 67-75 (2006).
75. Mehdorn, H. M. et al. High-field iMRI in glioblastoma surgery: improvement of resection radicality and survival for the patient? Acta Neurochir. Suppl. 109, 103-106 (2011).
76. Oszvald, A. et al. Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J. Neurosurg. 116, 357-364 (2012).
77. Kuhnt, D. et al. Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro Oncol. 13, 1339-1348 (2011).
78. Stummer, W. et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62, 564-576 (2008).
79. Simpson, J. R. et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 26, 239-244 (1993).
80. Rostomily, R. C. et al. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 35, 378-388 (1994).
81. Sanai, N., Polley, M. Y., McDermott, M. W., Parsa, A. T. & Berger, M. S. An extent of resection threshold for newly diagnosed glioblastomas. J. Neurosurg. 115, 3-8 (2011).
82. Wirtz, C. R. et al. Clinical evaluation and follow-up results for intraoperative magnetic resonance imaging in neurosurgery. Neurosurgery 46, 1112-1120 (2000).
83. Stummer, W. et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 42, 518-525 (1998).
84. Stummer, W. et al. Fluorescence-guided resection of glioblastoma multiforme by using 5 aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J. Neurosurg. 93, 1003-1013 (2000).
85. De Witt Hamer, P. C., Robles, S. G., Zwinderman, A. H., Duffau, H. & Berger, M. S. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J. Clin. Oncol. 30, 2559-2565 (2012).
86. Voorhies, R. M. et al. Intraoperative localization of subcortical brain tumors: further experience with B-mode real-time sector scanning. Neurosurgery 12, 189-194 (1983).
87. Kanno, H. et al. Intraoperative power Doppler ultrasonography with a contrast-enhancing agent for intracranial tumors. J. Neurosurg. 102, 295-301 (2005).
88. Grant, W. E., Hopper, C., MacRobert, A. J., Speight, P. M. & Bown, S. G. Photodynamic therapy of oral cancer: photosensitisation with systemic aminolaevulinic acid. Lancet 342, 147-148 (1993).
89. Regula, J. et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX-a pilot study. Gut 36, 67-75 (1995).
90. Schneider, J. P. et al. Intraoperative MRI to guide the resection of primary supratentorial glioblastoma multiforme-a quantitative radiological analysis. Neuroradiology 47, 489-500 (2005).
91. Senft, C. et al. Influence of iMRI-guidance on the extent of resection and survival of patients with glioblastoma multiforme. Technol. Cancer Res. Treat. 9, 339-346 (2010).
92. Senft, C. et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 12, 997-1003 (2011).
93. McGirt, M. J. et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J. Neurosurg. 110, 156-162 (2009).
94. Vuorinen, V., Hinkka, S., Farkkila, M. & Jaaskelainen, J. Debulking or biopsy of malignant glioma in elderly people-a randomised study. Acta Neurochir. (Wien) 145, 5-10 (2003).
95. Sawaya, R. et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42, 1044-1055 (1998).
96. Hegi, M. E. et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 26, 4189-4199 (2008).
97. Songtao, Q. et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 103, 269-273 (2012).
98. Weller, M. et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat. Rev. Neurol. 6, 39-51 (2010).
99. Savaskan, N. E., Fingerle-Rowson, G., Buchfelder, M. & Eyüpoglu, I. Y. Brain miffed by macrophage migration inhibitory factor. Int. J. Cell Biol. 2012, 139573 (2012).
100. Engelhorn, T. et al. Cellular characterization of the peritumoral edema zone in malignant brain tumors. Cancer Sci. 100, 1856-1862 (2009).
101. Savaskan, N. E. et al. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat. Med. 14, 629-632 (2008).
102. Savaskan, N. E. et al. Dissection of mitogenic and neurodegenerative actions of cystine and glutamate in malignant gliomas. Oncogene 30, 43-53 (2011).
103. Buckingham, S. C. et al. Glutamate release by primary brain tumors induces epileptic activity. Nat. Med. 17, 1269-1274 (2011).
104. Jain, R. K. et al. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8, 610-622 (2007).
105. Purow, B. & Schiff, D. Advances in the genetics of glioblastoma: are we reaching critical mass? Nat. Rev. Neurol. 5, 419-426 (2009).
106. Li, A. et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res. 69, 2091-2099 (2009).
107. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
108. MacDonald, T. J. et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat. Genet. 29, 143-152 (2001).
109. Tso, C. L. et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res. 66, 159-167 (2006).
110. Ruano, Y. et al. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am. J. Clin. Pathol. 131, 257-263 (2009).
111. Jenkins, R. B. et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 66, 9852-9861 (2006).
112. Cairncross, G. et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J. Clin. Oncol. 24, 2707-2714 (2006).
113. Weller, M. et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin. Cancer Res. 13, 6933-6937 (2007).
114. Belanich, M. et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 56, 783-788 (1996).
115. Jaeckle, K. A. et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J. Clin. Oncol. 16, 3310-3315 (1998).
116. Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350-1354 (2000).
117. Rivera, A. L. et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 12, 116-121 (2010).
118. Hegi, M. E. et al. Clinical trial substantiates the predictive value of O 6 methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 10, 1871-1874 (2004).
119. Stojic, L. et al. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev. 18, 1331-1344 (2004).
120. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005).
121. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
122. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
123. Chowdhury, R. et al. The oncometabolite 2 hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 12, 463-469 (2011).
124. Metellus, P. et al. IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J. Neurooncol. 105, 591-600 (2011).